[强]_老虎社区_美港股上老虎

foonfoon
2021-03-15

[强]

Merck and Gilead announce partnership for long-acting HIV treatments

Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize lon

Merck and Gilead announce partnership for long-acting HIV treatments

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":322465306,"tweetId":"322465306","gmtCreate":1615821312305,"gmtModify":1703493635312,"author":{"id":3576647402664342,"authorId":3576647402664342,"authorIdStr":"3576647402664342","name":"foonfoon","avatar":"https://static.tigerbbs.com/b53f6166b888bc10389b3d5ac7023052","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[强]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[强]&nbsp;</span></p></body></html>","text":"[强]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/322465306","repostId":1163783799,"repostType":4,"repost":{"id":"1163783799","pubTimestamp":1615820076,"share":"https://www.laohu8.com/m/news/1163783799?lang=&edition=full","pubTime":"2021-03-15 22:54","market":"us","language":"en","title":"Merck and Gilead announce partnership for long-acting HIV treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1163783799","media":"seekingalpha","summary":"Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize lon","content":"<p>Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to&nbsp;co-develop and co-commercialize&nbsp;long-acting treatments targeting people living with HIV.</p><p>The combination will bring together two experimental therapies of companies: Gilead’s capsid inhibitor, lenacapavir, and Merck’s nucleoside reverse transcriptase translocation inhibitor, islatravir.</p><p>The initial focus of the collaboration will be an oral formulation, and its studies are set to begin in H2 2021.</p><p>Gilead and Merck will share global development and commercialization costs on a 60%/40% basis, respectively with Gilead leading the commercialization in the U.S. while Merck focuses on the EU and the rest of the world.</p><p>The companies will equally share the global product revenues until a certain threshold is met, and after net product sales for the oral combination reaches $2B a year, Gilead and Merck will apportion any revenues above the threshold on a ratio of 65%/ 35% respectively.</p><p>In January, ViiV Healthcare, a joint venture between GlaxoSmithKline(NYSE:GSK), Pfizer(NYSE:PFE)and Shionogi(OTCPK:SGIOY)received FDA approval for Cabenuva, cited as the first and only once-monthly, long-acting&nbsp;regimen for the treatment of HIV.</p><p><img src=\"https://static.tigerbbs.com/d47453449984c6102db13dec7df70ce3\" tg-width=\"1083\" tg-height=\"495\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/035b5e3b38df0268f87dd33a8bde94ca\" tg-width=\"1083\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck and Gilead announce partnership for long-acting HIV treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck and Gilead announce partnership for long-acting HIV treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 22:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize long-acting treatments targeting people living with HIV.The combination will bring together two ...</p>\n\n<a href=\"https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1163783799","content_text":"Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize long-acting treatments targeting people living with HIV.The combination will bring together two experimental therapies of companies: Gilead’s capsid inhibitor, lenacapavir, and Merck’s nucleoside reverse transcriptase translocation inhibitor, islatravir.The initial focus of the collaboration will be an oral formulation, and its studies are set to begin in H2 2021.Gilead and Merck will share global development and commercialization costs on a 60%/40% basis, respectively with Gilead leading the commercialization in the U.S. while Merck focuses on the EU and the rest of the world.The companies will equally share the global product revenues until a certain threshold is met, and after net product sales for the oral combination reaches $2B a year, Gilead and Merck will apportion any revenues above the threshold on a ratio of 65%/ 35% respectively.In January, ViiV Healthcare, a joint venture between GlaxoSmithKline(NYSE:GSK), Pfizer(NYSE:PFE)and Shionogi(OTCPK:SGIOY)received FDA approval for Cabenuva, cited as the first and only once-monthly, long-acting regimen for the treatment of HIV.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}